Akebia Therapeutics, Inc.AKBANASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank62
3Y CAGR+74.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+74.9%/yr
vs -17.2%/yr prior
Acceleration
+92.1pp
Accelerating
Percentile
P62
Within normal range
vs 3Y Ago
5.4x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 65.62% |
| 2024 | -40.31% |
| 2023 | -62.00% |
| 2022 | 12.26% |
| 2021 | -32.33% |
| 2020 | -32.35% |
| 2019 | 10.96% |
| 2018 | 26.06% |
| 2017 | 99.42% |
| 2016 | 169.17% |